2-(2,6-dioxopiperidin-3-yl)-4-hydrazinylisoindole-1,3-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(2,6-dioxopiperidin-3-yl)-4-hydrazinylisoindole-1,3-dione
• 化学式: C₁₃H₁₂N₄O₄
• 分子量: 288.26
• InChiKey: LTZXEVQJTPAUIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  122
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] COMPOUNDS AND METHODS OF TREATING CANCERS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE CANCERS
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2020200291A1

  公开（公告）日：2020-10-08

  This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

  这份披露涉及异双功能化合物（例如，双功能小分子化合物），包括一种或多种异双功能化合物的组合物，以及使用这些异双功能化合物治疗患有特定疾病的需要该类治疗的受试者的方法。该披露还涉及识别此类异双功能化合物的方法。
• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
  申请人：FOGHORN THERAPEUTICS INC

  公开号：WO2020160198A1

  公开（公告）日：2020-08-06

  The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.

  本发明涉及用于治疗与BAF相关的疾病，如癌症和病毒感染的组合物和方法。
• Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
  申请人：Treston Anthony

  公开号：US20070105903A1

  公开（公告）日：2007-05-10

  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

  本发明涉及一组有效抑制血管生成的化合物。更具体地说，已经证明氮取代硫酰胺酰亚胺类似物和二取代硫酰胺酰亚胺类似物能够抑制血管生成。重要的是，这些化合物可以口服给药。
• BET protein degraders
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US10633386B2

  公开（公告）日：2020-04-28

  The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein B, R1, R5, Q1, Q″, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.

  本公开提供了式 I 所代表的化合物：及其药学上可接受的盐、水合物和溶液，其中 B、R1、R5、Q1、Q″、L、X、Y 和 Z 如说明书中所定义。本公开还提供了式 I 的化合物，用于治疗对 BET 溴链降解有反应的病症或紊乱，如癌症。
• Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
  申请人：Icahn School of Medicine at Mount Sinai

  公开号：US11472799B2

  公开（公告）日：2022-10-18

  Disclosed herein are serine threonine kinase (AKT) degradation/disruption compounds including an AKT ligand, a degradation/disruption tag, and a linker, and methods of using such compounds in the treatment of AKT-mediated diseases.

  本文公开了丝氨酸苏氨酸激酶（AKT）降解/破坏化合物，包括 AKT 配体、降解/破坏标签和连接体，以及使用此类化合物治疗 AKT 介导的疾病的方法。